News and Trends 9 Apr 2025 The biotech job market in 2025: Still in survival mode? …of remote biotech jobs. During the pandemic and in its immediate aftermath, remote roles helped decentralize the job market. But that trend has sharply reversed. Employers are now favoring candidates… April 9, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Nov 2024 Six exosome therapy companies driving development in the field …their candidates through the clinic. In this article, we take a look at six of the companies leading the way in the exosome therapy field. Table of contents Aegle Therapeutics … November 12, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Dec 2023 Nine biotech companies to watch in 2024 …noteworthy entry into the clinical-stage biopharmaceutical sector. At the heart of Aiolos Bio’s mission is AIO-001, a humanized anti-TSLP monoclonal antibody, developed as a treatment for moderate-to-severe asthma. This antibody… December 19, 2023 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 May 2017 In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight …Before its IPO, it attracted big-time investors like Medicxi and Sofinnova Partners, some of the top European biotech investors. The biotech has 3 different candidates at the clinical stage for… May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 Meet the Newest ALS Pioneer Company from Switzerland …drug candidates using cost-effective clinical strategies. If everything goes as planned, Chorus will step in in 2018, when the first human study of AL-S’ candidate is projected to begin. The… December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 Candidate found to inhibit malignant melanoma growth Malignant melanoma is a relatively aggressive type of skin cancer. When detected early, it is usually treatable by surgical resection only, but metastases develop, often spreading to distant areas. Currently,… March 31, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2016 This New Biotech wants to Regrow Neurons to cure Parkinson’s Mavalon Therapeutics will develop a drug candidate for Parkinson’s that can stop the disease progression by activating the growth of dying neurons. Mavalon Therapeutics, born today in the UK, will… October 18, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Apr 2025 HIV innovation: Six companies developing new treatments in 2025 …technology to target and remove latent viral DNA embedded within the host genome. Its lead candidate, EBT-101, employs an adeno-associated virus (AAV) delivery system to introduce CRISPR-Cas9 along with dual… April 16, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China …has been collaborating with Ablaze on an investigator-initiated trial of a radiopharmaceutical drug candidate targeted on PSMA. I am very glad to learn this novel candidate targeted on GPC3 by… March 31, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2017 French Biotech partners with Merck to Fight Tumor Resistance Domain Therapeutics and Merck have partnered up to develop immuno-oncology drug candidates that can boost the performance of checkpoint inhibitors. Domain Therapeutics has entered a collaboration and licensing agreement with… January 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Jun 2024 Ohio’s finest: Eight biotech companies leading the way …which is crucial for normal nervous system function. Convelo’s pipeline includes several small molecule candidates in preclinical development. In March 2024, the biotech discussed two new oral treatment candidates, CVL-1001… June 4, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 19 Jun 2024 MASH candidates make a splash after first drug approval …aim to reverse MASH That’s not all. California-based Akero Therapeutics is also in pursuit of MASH drug success. Its candidate efruxifermin (EFX) has been engineered to mimic fibroblast growth factor… June 19, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email